Relugolix is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment.
Currently, relugoli has been evaluated in nearly 1600 study participants in Phase 1, Phase 2, and phase 3 clinical trials. Relugolix, when taken orally once daily, can rapidly reduce estrogen and progesterone levels in women. The safety and efficacy of Relugolix was compared with that of leuprorelin in the treatment of uterine fibrosis in menorrhagia through a series of phase III clinical studies conducted in Japan, as well as the safety and effectiveness of the above two drugs in the treatment of pain symptoms associated with uterine fibrosis, the safety and effectiveness of relugolix for uterine fibroids were finally confirmed. In addition, a phase II clinical study of endometriosis and prostate cancer in relugolix has been conducted by Wutian Pharmaceutical, which confirmed that relugolix can significantly reduce the pain caused by endometriosis, it also reduces serum testosterone to castrate levels and significantly reduces prostate-specific antigen (PSA).
